

COUNSELLORS AT LAW 28 STATE STREET BOSTON, MASSACHUSETTS 02109-1784 TELEPHONE (617) 227-7400 FAX (617) 742-4214 le a lahiye com

JOHN A LAHIVE JR (1928-1997) THOMAS V SMURZYNSKI RALPH A LOREN GIULIO A DeCONTI, JR ANN LAMPORT HAMMITTE ELIZABETH A HANLEY AMY BAKER MANDRAGOURAS ANTHONY A LAURENTANO KEVIN J CANNING JANEE REMILLARD Deann FORAN SMITH PETER C LAURO JEANNE M DIGIORGIO DEBRA J MILASINCIC Ph D DAVID J RIKKERS DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER

CYNTHIA ANIK Ph D MEGANE WILLIAMS Ph D RICHA NAND MICHAEL PHILLIPPS . LISA M DIROCCO HATHAWAY P RUSSELL ***

SENIOR COUNSEL JAMES E COCKFIELD

OF COUNSEL JEREMIAH LYNCH WILLIAM A SCOFIELD JR

PATENT AGENTS THEODORER WEST SHAYNE'Y HUFE Phil DANIEL B. KI.

TECHNICAL SPECIALISTS MARIA LACCOTRIPE ZACHARAKIS, Ph.D.* CYNTHIA M SOROOS PETER W DINI Ph D **EUIHOON LEE** JENNIFER K ROSENFIELD ALLAN TAMESHTIT, Ph.D. CATHERINE E MICHERSON ERIC F WAGNER Ph D SHAHID HASAN Ph.D. JACOB G. WEINTRAUB PETER A DIMATTIA JONATHAN M SPARKS Ph.D. CRISTINE HOWLEY Ph.D. VINCENT P LOCCISANO MERIDETHIC ARNOLD

Admitted in NY only

** Passed the Patent Bar Examination *** Admitted in TX only

December 13, 2001

RECEIVED

TECH CENTER 1600.2900

Box Sequence

Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Patent Application Serial No. 09/662,478

Applicants:

Patrick J. Venta et al.

Filed: Title:

September 15, 2000 DNA ENCODING CANINEVON WILLEBRAND

FACTOR AND METHODS OF USE

UMV-1226CPPCUS Atty Docket:

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- 1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pages):
- 2. Transmittal Letter for Diskette Containing Sequence Listing (1 page);
- 3. Diskette Containing Computer Readable Form of Substitute Sequence Listing;
- 4. Paper Copy of Substitute Sequence Listing (pages 1-17):
- 5. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pages); and
- 6. Prepaid acknowledgment postcard.

Please charge any necessary fees to our Deposit Account No. 12-0080. The undersigned requests any extensions of time necessary to respond. A duplicate of this sheet is enclosed.

Certificate of First Class Mailing (37 C.F.R. §1.8(a))

I knowled world; they this transmitted latter and the namer

LAHIVE & COCKFIELD, LLP Attorneys at Law

a diffusiantica d hydrope addressed a Comment. Patents, Washington, D.C. 2025; on

December 11, 2001 Date

De Ann L. Smith, Esq.

Smith. Fra Attorney for Applicants



-IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Patrick J. Venta et al.

Serial No.: 09/662,478

Filed:

September 15, 2000

For:

DNA ENCODING CANINE VON

WILLEBRAND FACTOR AND METHODS OF USE

Attorney Docket No.: UMV-1226CPPCUS

Box Sequence Commissioner for Patents Washington, D.C. 20231 Group Art Unit: 1652

Examiner: not yet assigned

н ОЕМТЕВ 1600,290**0**

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Sequence, Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

December 11, 2001

Date of Signature and of Mail Deposit

By:

DeAnn F. Smith, Esq. Registration No. 36,683

Attorney for Applicants

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications

Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed from the

U.S. Patent and Trademark Office on October 11, 2001, we enclose a diskette which contains a

apaper eq. (1) the Sequence resting and a statement manual content of the Sequence resting appearing on pages 1-17 and the computer readable copy are the same as required under

Group Art Unit: 1652

37 C.F.R. 1.821(f). A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures is also enclosed herewith.

Immediately after the Abstract, please insert the hard (paper) copy of the substitute. Sequence Listing, numbered pages 1-17, submitted herewitn. No new matter has been added.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

DeAnn F. Smith, Esq. Registration No 36,683 Attorney for Applicants

28 State Street Boston, MA 02109 Tel. (617) 227-7400

Dated: December 11, 2001



· IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Patrick J. Venta et al.

Serial No.: 09/662,478

Filed:

September 15, 2000

For:

DNA ENCODING CANINE VON

WILLEBRAND FACTOR AND METHODS OF USE

Attorney Docket No.: UMV-1226CPPCUS

Box Sequence Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER FOR DISKETTE CONTAINING SEQUENCE LISTING

Dear Sir:

Enclosed is a diskette which contains a computer readable form of the Sequence Listing for the patent application filed herewith. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The material on this diskette is identical in substance to the sequence listing appearing on pages 1-17 of the Sequence Listing which is submitted herewith, as required by 37 C.F.R. § 1.821(f). The computer readable form of the sequence listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d).

Certificate of First Class Mailing (37 C.F.R. §1.8(a))

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Sequence, Commissioner for Patents, Washington, D.C. 20231 on:

LAHIVE & COCKFIELD, LLP Attorneys at Law

Group Art Unit: 1652

Examiner: not vet assigned

Bv:

DeAnn F. Smith, Esq.

DeAnn L. Smith, Esq.



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE

As we will be a significant

| March Control | March Control | March Control | March Control | MV-1226CFPCUS | MV-1226CFPCUS |

CONFIRMATION NO. 3602

000959 LAHIVE & COCKFIELD 28 STATE STREET BOSTON, MA 02109 FORMALITIES LETTER

****C000000006889438*

Date Mailed 10/11/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1 136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1. 1990), and 1114 QG 29 (May 1.5, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 QG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 QG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in fieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUSI be returned with the reply.

Customer Service:Center Immal Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE